Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 6;3:32. doi: 10.1038/s41698-019-0103-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Gene expression changes associated with BRCA1 mutation in ovarian cancer (OC) cells. a Survival (means ± s.e.m., n = 4) measured by the CCK8 assay of UWB1.289 OC cells (BRCA1-null) and UWB1.289 cells transfected with BRCA1 (BRCA1+) and treated with entinostat for 72 h. *P < 0.05 (t-test). b, c Western blot and densitometric analysis (means ± s.e.m., n = 3) of entinostat effects (72 h treatment) on H3K9ac b and H3K27ac c levels in BRCA1-null and BRCA1+ UWB1.289 OC cells. *P < 0.05 (t-test) relative to 0 entinostat. M, protein markers. d–f Unsupervised hierarchical clustering of differentially expressed genes measured by RNAseq between BRCA1-null and BRCA1+ d, entinostat-treated BRCA1+ compared with BRCA1+ e, and entinostat-treated BRCA1-null compared with BRCA1-null f UWB1.289 OC cells. Colored horizontal lines represent genes and columns represent specimens analyzed. Cells were treated with 0.5 μM entinostat for 24 h (n = 2). g Numbers of differentially expressed genes in BRCA1-null relative to BRCA1+UWB1.289 OC cells treated with 0.5 μM entinostat for 24 h (n = 2). h A Venn diagram shows numbers of common and unique differentially expressed genes determined by RNAseq in BRCA1+ and BRCA1-null UWB1.289 OC cells treated with 0.5 μM entinostat (Ent) for 24 h (n = 2).